Remdesivir in treatment of COVID-19: A systematic benefit-risk assessment

Miranda Davies, Vicki Osborne, Samantha Lane, Debabrata Roy, Sandeep Dhanda, Alison Evans, Saad Shakir
doi: https://doi.org/10.1101/2020.05.07.20093898

Article usage

Article usage: May 2020 to July 2025

AbstractFullPdf
May 202012650531
Jun 20202430330
Jul 20201440164
Aug 2020710113
Sep 202050068
Oct 2020510109
Nov 202045056
Dec 202029028
Jan 202137415
Feb 202152017
Mar 202144117
Apr 202183230
May 202166320
Jun 202158123
Jul 202139711
Aug 202143413
Sep 202125113
Oct 20214308
Nov 202130219
Dec 20212707
Jan 20223357
Feb 20221708
Mar 202214311
Apr 202225210
May 202251210
Jun 20221706
Jul 20221512
Aug 202216110
Sep 20222437
Oct 20221718
Nov 2022814
Dec 202211110
Jan 20231615
Feb 20231825
Mar 2023811
Apr 202320213
May 2023838
Jun 2023944
Jul 2023413
Aug 202318135
Sep 202316714
Oct 2023942
Nov 2023822
Dec 20231513
Jan 2024405
Feb 2024743
Mar 20241068
Apr 20241137
May 2024946
Jun 20241015
Jul 2024635
Aug 202410312
Sep 2024985
Oct 2024932
Nov 20241538
Dec 2024816
Jan 2025448
Feb 20253195
Mar 2025273214
Apr 202521108
May 20251656
Jun 202524114
Jul 202519179
Back to top
Posted May 12, 2020.
Download PDF
Data/Code
Email
Remdesivir in treatment of COVID-19: A systematic benefit-risk assessment
Miranda Davies, Vicki Osborne, Samantha Lane, Debabrata Roy, Sandeep Dhanda, Alison Evans, Saad Shakir
medRxiv 2020.05.07.20093898; doi: https://doi.org/10.1101/2020.05.07.20093898
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area